Yuting Shao

Yuting Shao

Auto-generated profile, based on publicly available information

Yuting Shao

School of Pharmacy, Nantong University, 9 Seyuan Road, Nantong 226019, P. R. China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
YSYuting Shao
Yuting Shao
YCYun Chen
Yun Chen
QZQingyu Zhu
Qingyu Zhu
LYLingyan Yi
Lingyan Yi
YMYifan Ma
Yifan Ma
WYWenjuan Yao
Wenjuan Yao

7 June 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JSJingwen Sun
Jingwen Sun
YSYuting Shao
Yuting Shao
LPLele Pei
Lele Pei
QZQingyu Zhu
Qingyu Zhu
XYXiaoqiang Yu
Xiaoqiang Yu
WYWenjuan Yao
Wenjuan Yao
The roles and mechanisms of A-kinase anchoring protein 1 (AKAP1) in vascular smooth muscle cell (VSMC) phenotypic modulation and neointima formation are currently unknown. AKAP1 is a mitochondrial PKA-anchored protein and maintains mitochondrial homeostasis. This study aimed to investigate how AKAP1/PKA signaling plays a protective role in inhibiting VSMC phenotypic transformation and neointima formation by regulating mitochondrial fission. The results showed that both PDGF-BB treatment and balloon injury reduced the transcription, expression, and mitochondrial anchoring of AKAP1. In vitro, the overexpression of AKAP1 significantly inhibited PDGF-BB mediated VSMC proliferation and migration, whereas AKAP1 knockdown further aggravated VSMC phenotypic transformation. Additionally, in the balloon injury model in vivo, AKAP1 overexpression reduced neointima formation, the muscle fiber area ratio, and rat VSMC proliferation and migration. Furthermore, PDGF-BB and balloon injury inhibited Drp1 phosphorylation at Ser637 and promoted Drp1 activity and mitochondrial midzone fission; AKAP1 overexpression reversed these effects. AKAP1 overexpression also inhibited the distribution of mitochondria at the plasma membrane and the reduction of PKARIIβ expression induced by PDGF-BB, as evidenced by an increase in mitochondria-plasma membrane distance as well as PKARIIβ protein levels. Moreover, the PKA agonist promoted Drp1 phosphorylation (Ser637) and inhibited PDGF-BB-mediated mitochondrial fission, cell proliferation, and migration. The PKA antagonist reversed the increase in Drp1 phosphorylation (Ser637) and the decline in mitochondrial midzone fission and VSMC phenotypic transformation caused by AKAP1 overexpression. The results of this study reveal that AKAP1 protects VSMCs against phenotypic modulation by improving Drp1 phosphorylation at Ser637 through PKA and inhibiting mitochondrial fission, thereby preventing neointima formation.